An Early Warning System: How Continuous MRD Testing Can Predict Myeloma Relapse Years in Advance

For myeloma patients who achieve the milestone of being MRD-negative, continuous monitoring is critical. A major new study presented by Anna Smit, MSc, at the IMS 2025 conference proves that a patient's status changing from MRD-negative back to MRD-positive is a powerful early warning sign of a future clinical relapse.

Crucially, this "molecular relapse" happens, on average, nearly a year and a half before the disease becomes clinically apparent, creating a vital window of opportunity for doctors to intervene and potentially change a patient's outcome.

Beyond a single snapshot: The power of tracking MRD over time

Minimal Residual Disease (MRD) testing uses highly sensitive technology to detect even one cancer cell among 100,000 healthy cells. Achieving an MRD-negative status is a primary goal of myeloma treatment and is strongly linked to longer remissions. But the story doesn't end there. The key question this research sought to answer was: What does it mean if the MRD test becomes positive again?

To find out, researchers used data from the large-scale CASSIOPEIA clinical trial. This study was ideal because it included frequent, long-term MRD monitoring for over 1,000 newly diagnosed patients. The analysis focused on the 583 patients who became MRD-negative, tracking their status over a median of six years. They found that while most (65%) remained MRD-negative, a significant portion (27%) converted back to MRD-positive within five years.

A dynamic model: A personalized, real-time risk calculator

The central innovation of this research was the use of a dynamic prediction model. Unlike a static risk score that is calculated once at the beginning of treatment, a dynamic model acts like a real-time risk calculator.

Think of it like a weather app. A static model is like getting a single forecast for your entire trip before you leave. A dynamic model is like the app on your phone, constantly updating the forecast based on your current location and changing conditions. This new model incorporates a patient's baseline risk factors, their treatment history, and, most importantly, every new MRD test result to provide a continuously updated, highly personalized prediction of their risk of relapse.

The 18-month warning: What the study found

The dynamic model confirmed that tracking MRD over time provides invaluable information.

MRD Conversion is a Powerful Predictor: A change from MRD-negative to MRD-positive was a highly significant predictor of future clinical progression.

Window of opportunity

The most critical finding was the time lag between this molecular relapse and a clinical relapse. The median time was 17.7 months. This nearly year-and-a-half lead time gives doctors a crucial window to potentially adjust treatment or follow-up care before a patient develops symptoms or the disease shows up on standard tests.

Maintenance Therapy Matters: An exploratory analysis suggested that patients receiving daratumumab maintenance therapy who converted to MRD-positive still had a longer time before their disease progressed, indicating the therapy may slow down the relapse.

This research transforms the role of MRD testing from a simple one-time prognostic marker into a dynamic surveillance tool. For patients, achieving an MRD-negative state is a critical goal, but this study proves that the journey doesn't end there. Continuous monitoring provides an invaluable early warning system. By detecting a molecular relapse long before clinical symptoms appear, doctors are given a crucial window to act, paving the way for a future of MRD-guided therapy where treatment can be adjusted proactively to keep the disease under control for longer.

HealthTree Foundation's weekly newsletter delivers myeloma news, breaking conference research, FDA approvals, side effect management, patient stories, and more right to your inbox.

Sign Up Today!